English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Abasaglar (Abasria) (insulin glargine) – Conditions or restrictions regarding supply and use - A10AE04

Updated on site: 05-Oct-2017

Medication nameAbasaglar (Abasria)
ATC CodeA10AE04
Substanceinsulin glargine
ManufacturerEli Lilly Regional Operations GmbH

A. MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturers of the biological active substance

Lilly del Caribe, Inc.

12.3 km 65th Infantry Road Carolina, PR 00985

Puerto Rico

Eli Lilly and Company

Indianapolis

Indiana 46285

USA

Name and address of the manufacturer responsible for batch release

ABASAGLAR 100 units/mL solution for injection in a cartridge and pre-filled pen

Lilly France S.A.S.

2, rue du Colonel Lilly F-67640 Fegersheim France

ABASAGLAR 100 units/mL solution for injection in a cartridge

Eli Lilly Italia S.p.A.,

Via Gramsci 731-733,

50019 Sesto Fiorentino, (FI)

Italy.

B.CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

Medicinal product subject to medical prescription

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

Periodic safety update reports

The marketing authorisation holder shall submit periodic safety update reports for this product in accordance with the requirements set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and published on the European medicines web- portal.

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT

Risk Management Plan (RMP)

The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

At the request of the European Medicines Agency;

Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

If the submission of a PSUR and the update of a RMP coincide, they can be submitted at the same time.

Comments

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
  • Help
  • Get it on Google Play
  • About
  • Info on site by:

  • Presented by RXed.eu

  • 27558

    prescription drugs listed